Immuno-oncology digests #5: Leveraging potently tumor-reactive TCRs for cellular therapy
NEW In this webinar, Dr. Wouter Scheper, Senior Postdoctoral Fellow from The Netherlands Cancer Institute, will discuss how leveraging potently tumor-reactive T cell receptors can be useful for effective cell therapy for cancer. He will also demonstrate how looking into the intercellular interactions, also known as cell avidity, helps provide valuable information to identify potent TCR T cells.
- Time and Date
June 1, 2022 10:00 AM CET/ 04:00 PM CST
June 1, 2022 04:00 PM CET/ 09:00 AM CT/ 10:00 AM ET
Dr. Wouter Scheper, Senior Postdoctoral Fellow from The Netherlands Cancer Institute
Immuno-oncology digests #4: TCR signal strength defines distinct mechanisms of T-cell dysfunction and cancer evasion (journal club)
In this webinar, we discussed the recent work by Shakiba and colleagues, who take a different approach modifying the tumor associated antigen to examine the impact of TCR signaling strength, what they might mean for cellular therapies, and how incorporating cell avidity measurements with z-Movi® Cell Avidity Analyzer can be used to create a more comprehensive understanding of a cellular product and predict in vivo outcomes.
Are you interested to learn about different immuno-oncology related topics?
Keynote speaker webinars
Seminars from world-leading experts
Don’t miss world-renowned researchers talk about their experience with cell avidity measurements for T cell functionality prediction.
Learn about Leucid Bio’s efforts in developing a next-generation CAR platform, known as parallel (p)CAR. In this webinar, Dr. John Maher demonstrated how to use the z-Movi to address the importance of relative binding affinity in the design of optimized pCAR?
Learn from Dr. Maria Themeli how to overcome low antigen density and improve CAR-T cell persistence with multi-targeting and co-stimulation through increasing synaptic avidity with the z-Movi.
Learn from Prof. Lowdell how primed NK cells become effective against resistant tumor cells, and how cell avidity measurements were used to depict a stronger binding of primed NK cells, resulting in improved tumor cell killing.
Learn from Prof. de Larrea how expressing two CARs on a single cell enhances the strength of CAR T-cell/target cell interactions, prevents BCMA escape-driven relapse, and how cell avidity measurements contributed to their findings.
Deep-dive into the applications with LUMICKS’ scientists
Watch our webinars presented by expert speakers, covering the latest breakthroughs and developments in immuno-oncology.
Explore experiments across the topics of CAR-T cells, TCR T cells, NK cells, and bispecific antibody-engaged T cells, showing a correlation between avidity and T cell functionality.
Discover how measuring cellular avidity using the z-Movi Cell Avidity Analyzer helps researchers to quickly identify optimal functioning CARs and compare between panels.
How does the z-Movi Cell Avidity Analyzer measure cell avidity? Why does avidity matter in TCR-dependent T-cell cytotoxicity? How does it compare with functional assays?
We present avidity data, obtained by Dr. Nathalie Rufer’s research team at the University of Lausanne, showing a linear correlation between T cell function and cell avidity.